Scholar Rock Holding Corporation (SRRK)
| Market Cap | 5.37B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -377.94M |
| Shares Out | 114.88M |
| EPS (ttm) | -3.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,413,473 |
| Open | 46.89 |
| Previous Close | 46.29 |
| Day's Range | 45.97 - 48.23 |
| 52-Week Range | 27.07 - 51.63 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 56.17 (+20.2%) |
| Earnings Date | May 7, 2026 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or laten... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $56.17, which is an increase of 20.20% from the latest price.
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common sto...
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The...
Scholar Rock Holding Transcript: Status update
Apitegromab’s BLA has been resubmitted to the FDA with two fill-finish facilities, offering dual paths to approval and robust supply chain flexibility. Launch preparations are advanced, with sufficient inventory and payer engagement underway. EMA review is on track for mid-2026.
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi...
Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference
The company is preparing for U.S. and European launches of its first-in-class myostatin inhibitor for SMA, supported by strong clinical data and a robust financial position. Regulatory delays are being addressed, with commercial and pipeline expansion plans advancing globally.
Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026
Apitegromab's approval was delayed due to manufacturing compliance, but remediation and regulatory engagement are progressing, with a 2026 U.S. launch targeted. Commercial and supply chain readiness are strong, global expansion is planned, and financial resources are robust.
Scholar Rock Holding Transcript: TD Cowen 46th Annual Health Care Conference
Apitegromab is positioned for U.S. and European launches in 2026, pending resolution of manufacturing compliance at the Indiana facility and validation of a second site. Robust demand and a multi-billion dollar opportunity are anticipated, with pipeline expansion into FSHD and other neuromuscular diseases underway.
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0...
Scholar Rock Holding Earnings Call Transcript: Q4 2025
Apitegromab is on track for U.S. and EU launches in 2026, pending regulatory approvals, with strong commercial and supply chain preparations underway. Financially, the company ended 2025 with $368M in cash and secured a $550M debt facility to support launch and pipeline advancement.
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...
Scholar Rock to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial m...
Scholar Rock Holding Transcript: 44th Annual J.P. Morgan Healthcare Conference
Apitegromab is set for U.S. and European launches in 2026 after strong phase III results in SMA, with expansion into FSHD and other neuromuscular diseases planned. The company is financially positioned for growth, with a $2B+ market opportunity and global commercialization strategy.
Scholar Rock Highlights 2026 Strategic Priorities
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...
Scholar Rock Holding Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant transformation in 2025 included positive Phase 3 results for apitegromab in SMA, a BLA filing, and leadership changes. Regulatory delays due to manufacturing issues shifted the anticipated U.S. launch to 2026, allowing more time for commercial preparation and global expansion.
Scholar Rock Holding Transcript: Citi Annual Global Healthcare Conference 2025
Apitegromab is poised to become the first muscle-targeted therapy for SMA, with strong phase III data supporting its use alongside existing SMN therapies. Regulatory approval is delayed due to manufacturing issues, but launch is expected in 2026, supported by a robust financial position and plans for global expansion.
Scholar Rock Holding Transcript: Jefferies London Healthcare Conference 2025
Apitegromab's approval is delayed due to manufacturing compliance issues, but remediation is nearly complete and FDA reinspection is expected in early 2025. Commercial launch plans target SMA patients on existing therapies, with global expansion and a strong financial runway into 2027.
Scholar Rock Holding Earnings Call Transcript: Q3 2025
Apitegromab's U.S. approval was delayed due to manufacturing compliance, not efficacy. The company expects to resubmit its BLA after facility remediation, with a 2026 launch targeted. Financials remain strong, with a cash runway into 2027 and strategic investments prioritized.
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open....
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA)...
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Tuesday.